Caris Life Sciences, Inc.
CAIHealthcareNASDAQBiotechnology · Last scanned May 29, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Caris Life Sciences, Inc. focuses on Biotechnology services and products. Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. At a $4.71B market cap, Caris Life Sciences, Inc. ranks as a mid-cap company within healthcare. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms.
Market Cap
$4.71B
Beta
—
P/E (TTM)
—
P/E (Fwd)
44.74
EPS (TTM)
$-2.76
EPS (Fwd)
$0.37
ROE
28.3%
ROA
9.3%
Cash
$823.5M
Total Debt
$431.0M
Free CF
$102.1M
52W Change
-40.5%
Annual Financials
Cash vs Debt
With $823.5M in cash and $431.0M in debt, CAI maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $102.1M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 28.3% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 9.3% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $258.5M (2022) to $812.0M (2025), reflecting a 214% increase over the period.
Investors considering Caris Life Sciences, Inc. should weigh the typical risks associated with CAI's sector, size, and financial profile against their own risk tolerance and investment objectives. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Caris Life Sciences, Inc. and its sector.